BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clin Cancer Res 2016;22:3218-26. [PMID: 26839145 DOI: 10.1158/1078-0432.CCR-15-2422] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Labriet A, Lévesque É, Cecchin E, De Mattia E, Villeneuve L, Rouleau M, Jonker D, Couture F, Simonyan D, Allain EP, Buonadonna A, D'Andrea M, Toffoli G, Guillemette C. Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. Sci Rep 2019;9:13008. [PMID: 31506518 DOI: 10.1038/s41598-019-49477-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wu S, Yang X, Tang W, Familiari G, Relucenti M, Aschner M, Li X, Chen R. Chemotherapeutic Risk lncRNA-PVT1 SNP Sensitizes Metastatic Colorectal Cancer to FOLFOX Regimen. Front Oncol 2022;12:808889. [DOI: 10.3389/fonc.2022.808889] [Reference Citation Analysis]
3 Kong X, Sawalha AH. Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex. Ann Rheum Dis 2019;78:1388-97. [PMID: 31315839 DOI: 10.1136/annrheumdis-2019-215567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 Papachristos A, Sivolapenko GB. Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review. J Pers Med 2020;10:E79. [PMID: 32759686 DOI: 10.3390/jpm10030079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Li J, Huang L, Zhao H, Yan Y, Lu J. The Role of Interleukins in Colorectal Cancer.Int J Biol Sci. 2020;16:2323-2339. [PMID: 32760201 DOI: 10.7150/ijbs.46651] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
6 Peng X, Shi J, Sun W, Ruan X, Guo Y, Zhao L, Wang J, Li B. Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis. Oncotarget 2018;9:12351-64. [PMID: 29552316 DOI: 10.18632/oncotarget.24033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
7 Zhai K, Yang Y, Gao ZG, Ding J. Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer. Oncotarget 2017;8:44490-7. [PMID: 28548958 DOI: 10.18632/oncotarget.17771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bazzichetto C, Conciatori F, Falcone I, Cognetti F, Milella M, Ciuffreda L. Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer. J Oncol 2019;2019:5373580. [PMID: 31191652 DOI: 10.1155/2019/5373580] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
9 Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69-80. [PMID: 28787661 DOI: 10.1016/j.ejca.2017.07.016] [Cited by in Crossref: 98] [Cited by in F6Publishing: 106] [Article Influence: 19.6] [Reference Citation Analysis]
10 Shi W, Men L, Pi X, Jiang T, Peng D, Huo S, Luo P, Wang M, Guo J, Jiang Y, Peng L, Lin L, Li S, Lv J. Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL‑6/STAT3 signaling pathway. Int J Oncol 2021;59:99. [PMID: 34726248 DOI: 10.3892/ijo.2021.5279] [Reference Citation Analysis]
11 Piffoux M, Eriau E, Cassier PA. Autophagy as a therapeutic target in pancreatic cancer. Br J Cancer 2021;124:333-44. [PMID: 32929194 DOI: 10.1038/s41416-020-01039-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
12 Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018;9:29820-29841. [PMID: 30038723 DOI: 10.18632/oncotarget.25661] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]